123 related articles for article (PubMed ID: 9373810)
1. Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy.
Jacobson GA; Peterson GM; McLean S
J Clin Pharm Ther; 1997 Apr; 22(2):119-26. PubMed ID: 9373810
[TBL] [Abstract][Full Text] [Related]
2. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
Bergés R; Segura J; Ventura R; Fitch KD; Morton AR; Farré M; Mas M; de La Torre X
Clin Chem; 2000 Sep; 46(9):1365-75. PubMed ID: 10973867
[TBL] [Abstract][Full Text] [Related]
3. Blood and urinary concentrations of salbutamol in asthmatic subjects.
Elers J; Pedersen L; Henninge J; Lund TK; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2010 Feb; 42(2):244-9. PubMed ID: 19927035
[TBL] [Abstract][Full Text] [Related]
4. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
Ventura R; Segura J; Bergés R; Fitch KD; Morton AR; Berruezo S; Jiménez C
Ther Drug Monit; 2000 Jun; 22(3):277-82. PubMed ID: 10850394
[TBL] [Abstract][Full Text] [Related]
5. Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
Tomlinson HS; Corlett SA; Allen MB; Chrystyn H
Br J Clin Pharmacol; 2005 Dec; 60(6):605-10. PubMed ID: 16305584
[TBL] [Abstract][Full Text] [Related]
6. New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation.
Mazhar SH; Chrystyn H
J Pharm Biomed Anal; 2009 Sep; 50(2):175-82. PubMed ID: 19443162
[TBL] [Abstract][Full Text] [Related]
7. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
[TBL] [Abstract][Full Text] [Related]
8. Inhaled procaterol versus salbutamol in bronchial asthma.
Liippo K; Silvasti M; Tukiainen H
Eur J Clin Pharmacol; 1991; 40(4):417-8. PubMed ID: 1828765
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of efficacy of salbutamol via metered dose inhaler with volumatic spacer and via dry powder inhaler, easyhaler, to nebulization in mild to moderate severity acute asthma exacerbation in childhood.
Vangveeravong M
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S115-23. PubMed ID: 19253506
[TBL] [Abstract][Full Text] [Related]
10. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
[TBL] [Abstract][Full Text] [Related]
11. Altered cardiovascular autonomic regulation after 2-week inhaled salbutamol treatment in asthmatic children.
Jartti TT; Kaila TJ; Tahvanainen KU; Kuusela TA; Vanto TT; Välimäki IA
Eur J Pediatr; 1997 Nov; 156(11):883-8. PubMed ID: 9392406
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Clin J Sport Med; 2012 Mar; 22(2):140-5. PubMed ID: 22388343
[TBL] [Abstract][Full Text] [Related]
13. Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients.
Anderson WJ; Short PM; Williamson PA; Morrison AE; Palmer C; Tavendale R; Lipworth BJ
Clin Sci (Lond); 2014 Jan; 126(1):75-83. PubMed ID: 23829494
[TBL] [Abstract][Full Text] [Related]
14. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma.
Sykes AP; Ayres JG
Respir Med; 1990 Mar; 84(2):135-8. PubMed ID: 2371435
[TBL] [Abstract][Full Text] [Related]
15. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group.
Britton MG; Earnshaw JS; Palmer JB
Eur Respir J; 1992 Oct; 5(9):1062-7. PubMed ID: 1426215
[TBL] [Abstract][Full Text] [Related]
16. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma.
Szczeklik A; Mastalerz L; Nizankowska E; Cmiel A
Am J Respir Crit Care Med; 1996 Feb; 153(2):567-71. PubMed ID: 8564099
[TBL] [Abstract][Full Text] [Related]
17. Inhaled salbutamol and doping control: effects of dose on urine concentrations.
Sporer BC; Sheel AW; Taunton J; Rupert JL; McKenzie DC
Clin J Sport Med; 2008 May; 18(3):282-5. PubMed ID: 18469572
[TBL] [Abstract][Full Text] [Related]
18. (R,S)-salbutamol plasma concentrations in severe asthma.
Jacobson GA; Chong FV; Wood-Baker R
J Clin Pharm Ther; 2003 Jun; 28(3):235-8. PubMed ID: 12795782
[TBL] [Abstract][Full Text] [Related]
19. Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects.
Midgren B; Melander B; Persson G
Chest; 1992 Apr; 101(4):1019-22. PubMed ID: 1348219
[TBL] [Abstract][Full Text] [Related]
20. Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study.
Brambilla C; Le Gros V; Bourdeix I;
Clin Ther; 2003 Jul; 25(7):2022-36. PubMed ID: 12946548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
